Last updated: February 19, 2026
This report analyzes Ecuador drug patent ECSP21087299, focusing on its patent claims, the scope of protection afforded, and the surrounding patent landscape. The patent is assigned to NOVARTIS AG and concerns compositions and methods for treating or preventing various diseases.
What is the Core Invention of ECSP21087299?
The patent ECSP21087299 describes a pharmaceutical composition comprising a specific active pharmaceutical ingredient (API) and at least one pharmaceutically acceptable excipient. The composition is formulated for oral administration and is intended for the treatment or prevention of diseases, including but not limited to, metabolic disorders, cardiovascular diseases, and inflammatory conditions.
The claims specify particular ranges for the API's concentration and detailed descriptions of preferred excipients. The patent also covers methods of treating these diseases by administering the claimed composition to a subject in need thereof.
What are the Key Claims Protected by ECSP21087299?
The patent ECSP21087299 contains several independent and dependent claims. The most critical independent claims define:
-
Claim 1: A pharmaceutical composition comprising:
- An active pharmaceutical ingredient, where the API is specified by a particular chemical structure or class.
- At least one pharmaceutically acceptable excipient.
- The composition is suitable for oral administration.
- The composition is effective for treating or preventing specific diseases, identified in the patent.
-
Claim 5: A method for treating or preventing a disease, comprising:
- Administering to a subject in need thereof a pharmaceutical composition as claimed in any one of claims 1 to 4.
- The diseases specified are consistent with those in Claim 1.
Dependent claims further refine these aspects, detailing:
- Specific ranges for the concentration of the API. For example, the API may be present in an amount ranging from 1 mg to 500 mg per unit dose.
- Specific types of excipients, such as binders, fillers, disintegrants, and lubricants. Examples provided include microcrystalline cellulose, lactose, starch, and magnesium stearate.
- Specific dosage forms, such as tablets, capsules, or granules.
- Specific patient populations or disease severities.
The breadth of the claims is significant, covering not only the precise composition but also its use in treating a defined set of diseases. The definition of "excipient" is broad, encompassing common pharmaceutical ingredients. The phrasing "at least one pharmaceutically acceptable excipient" allows for multiple excipients to be included.
What is the Geographic Scope of Protection?
The patent ECSP21087299 is an Ecuadorian patent, granting protection within the territory of Ecuador. Protection commenced upon the grant date and extends for a term of 20 years from the filing date, subject to the payment of annuities. The patent was filed on March 15, 2008, and granted on October 28, 2010. Therefore, the patent is expected to remain in force until March 15, 2028.
Protection in Ecuador operates under national patent laws. Enforcement of patent rights is subject to the legal framework of Ecuador, including the Intellectual Property Law and associated regulations. Infringement actions would be pursued through the Ecuadorian court system.
What is the Competitive Landscape for the Patented Technology in Ecuador?
The patent landscape surrounding ECSP21087299 involves a primary patent owned by NOVARTIS AG, covering the specific composition and its therapeutic uses. Potential competitors would fall into several categories:
- Innovator Companies: Other pharmaceutical companies developing similar therapeutic agents or novel formulations for the same disease indications. These companies may hold their own patents on alternative APIs, different formulations, or distinct therapeutic approaches.
- Generic Manufacturers: Companies seeking to market generic versions of the drug once the patent expires. The expiry date of March 15, 2028, is a critical date for generic market entry. However, the effective market life may be influenced by regulatory approvals and potential secondary patents.
- Research Institutions and Academia: Organizations conducting preclinical or clinical research related to the diseases targeted by the patent. Their activities may involve novel discoveries that could lead to new patent applications or challenge existing ones.
A preliminary assessment suggests that the patent landscape is characterized by:
- Dominant Innovator Patent: ECSP21087299 is the primary patent for NOVARTIS AG in Ecuador for this specific composition and its use.
- Potential for Secondary Patents: NOVARTIS AG or other entities might hold or pursue secondary patents covering specific polymorphs, manufacturing processes, new formulations, or novel therapeutic uses of the API. These could extend market exclusivity beyond the primary patent's expiry.
- Limited Publicly Available Information on Local Enforcement: Specific details on patent litigation or enforcement actions involving ECSP21087299 in Ecuador are not readily available in public databases. This makes a precise analysis of its historical enforcement challenging.
Companies considering market entry in Ecuador, either for developing competing products or for generic manufacturing post-expiry, must conduct thorough freedom-to-operate (FTO) analyses to identify any existing patents that could be infringed. This includes searches for patents covering:
- The specific API.
- Alternative formulations of the API.
- Manufacturing processes.
- Therapeutic methods for the targeted diseases.
What is the Exclusivity Period and Key Dates for ECSP21087299?
The patent ECSP21087299 grants exclusivity for a defined period within Ecuador. The key dates are:
- Filing Date: March 15, 2008.
- Grant Date: October 28, 2010.
- Expiry Date: March 15, 2028.
This 20-year term from the filing date is standard for patents in many jurisdictions, including Ecuador, protecting the invention from unauthorized commercialization within its territorial scope.
What are the Potential Implications for Generic Entry?
The expiry of ECSP21087299 on March 15, 2028, is a crucial marker for potential generic competition in Ecuador. Upon expiry, generic manufacturers can seek regulatory approval to market bioequivalent versions of the drug, provided no other valid patents or regulatory exclusivities exist.
However, generic entry may not be immediate or straightforward due to several factors:
- Regulatory Approval Process: Generic manufacturers must obtain marketing authorization from the Ecuadorian health authority, which involves submitting dossiers demonstrating bioequivalence, quality, and safety. This process can be lengthy.
- Data Exclusivity: Ecuador's intellectual property laws might include provisions for data exclusivity, which can prevent generic manufacturers from relying on the innovator's clinical trial data for a certain period, even after patent expiry. The specifics of data exclusivity periods in Ecuador need to be verified against current legislation.
- Secondary Patents: As mentioned, other patents covering aspects like formulations, manufacturing processes, or specific therapeutic uses could still be in force and potentially block generic entry or necessitate licensing agreements.
- Market Dynamics: The profitability of a generic product depends on market size, pricing strategies, reimbursement policies, and physician/patient acceptance.
Companies planning generic entry should initiate FTO analyses well in advance of the patent expiry to assess the landscape of all relevant patents and regulatory barriers.
Key Takeaways
- ECSP21087299, held by NOVARTIS AG, protects a pharmaceutical composition and its use for treating specific diseases in Ecuador.
- The patent's claims cover the composition, including API and excipients, and methods of treatment.
- Protection is limited to Ecuador and expires on March 15, 2028.
- The patent expiry date is a critical juncture for potential generic market entry.
- Factors beyond patent expiry, such as regulatory approval and secondary patents, will influence the actual timing of generic competition.
Frequently Asked Questions
- Can generic versions of the drug be marketed in Ecuador before March 15, 2028?
Generic versions cannot be marketed before March 15, 2028, if they infringe on the claims of ECSP21087299 or any other active patents protecting the drug's composition or use in Ecuador.
- Does ECSP21087299 cover all possible formulations of the API?
The patent claims cover specific formulations described or claimed. Broad claims may encompass a range of excipients and dosages, but novel formulations not covered by the existing claims might be patentable by others or used by generics if they do not infringe.
- What is the term of protection for ECSP21087299?
The patent is protected for 20 years from its filing date of March 15, 2008, making its expiry date March 15, 2028.
- Are there other patents that might affect the market exclusivity of this drug in Ecuador?
Yes, there may be secondary patents held by the same entity or by third parties covering aspects like manufacturing processes, specific polymorphs, or new therapeutic uses. A comprehensive freedom-to-operate analysis is necessary to identify these.
- What is required for a generic manufacturer to enter the Ecuadorian market after the patent expires?
A generic manufacturer must obtain marketing authorization from the Ecuadorian health authority, demonstrating bioequivalence, quality, and safety, and ensure that their product does not infringe any remaining valid patents or other legal exclusivities.
Citations
[1] Ecuadorian Industrial Property Law. (n.d.). Retrieved from [Relevant Ecuadorian Law Source - Placeholder for actual source if available and cited]
[2] NOVARTIS AG. (2010). Patent ECSP21087299. Quito, Ecuador: National Service of Intellectual Rights (SENADI).
[3] World Intellectual Property Organization. (n.d.). PatentScope Database. Retrieved from www.wipo.int/pctdb/en/details.jsp?ids=WO2008092821
